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NATIONAL MARKETING GONE UNINTENTIONALLY
GLOBAL: DIRECT-TO-CONSUMER ADVERTISING OF
PHARMACEUTICAL PRODUCTS AND
THE INTERNET
Jacqueline West*

I. INTRODUCTION
Take a moment to recall the last time you saw a prescription medication advertised
on television or the radio. What was your perception of the information conveyed in the
advertisement? Did you believe the claims the advertisement made? Now, take a moment to
think about the last time you logged on to the Internet to research a medical symptom you, a
family member, or a friend had experienced. Did you trust the information you found on the
Internet, and if so, did you act upon it in some way? You are probably aware of, at least, a few
people who have acted upon information they learned over the Internet regarding a prescription medication. Such actions may have been as casual as discussing the information with a
friend, or as direct as going to a physician to request the researched medication.
Pharmaceutical advertising is an immense (and influential) business.' In 2009 the
biopharmaceutical industry spent $4.5 billion on direct-to-consumer ("DTC") advertising in
such media as television, radio and the Internet. 2 DTC advertising of pharmaceutical products
has become an expected phenomenon in American life. 3 This is not so in other countries, as
only the U.S. and New Zealand allow DTC advertising of pharmaceutical products in any
medium. 4 However, searching for health information on the Internet is a widespread practice,
both in the United States ("U.S.") 5 and in Europe. 6 One study found that much of the health
* J.D. Candidate, 2013, Maurice A. Deane School of Law at Hofstra University. I would like to thank the staff
of the Journal of International Business & Law for both giving me this opportunity and editing and preparing
this Note for publication. Special thanks to Professors Alan Jakimo and Janet Dolgin for advising me
throughout the writing process. To Professor Tracy Dunbrook, for providing me with excellent support and
constructive criticism through the editing process, I could not have done it without you. And finally, to my
wonderful network of family and friends, without whose support and encouragement I would have never
undertaken the adventure of law school.
1 In 2010, the pharmaceutical industry invested over $67 billion dollars in research and development, and in
2008 contributed $333 billion to the United States Gross Domestic Product, directly employed over 650,000
people, and indirectly employed over 3 million people. Pharmaceutical Industry Profile 2011,
PHARMACEUTICAL MFRS. OF AMERICA (2011), at iii-8, available at http://www.phrma.org/sites/default/files/159/

phrmaprofile_2011_final.pdf.
2 Press Release, The Nielsen Co., U.S. Ad Spend Down Nine Percent in 2009, Nielsen Says (Feb. 24, 2010),
available at http://blog.nielsen.com/nielsenwire/wp-content/uploads/2010/02/2009-Year-End-Ad-Spend-PressRelease.pdf.
3 Nathan Jessop, Will DTC Advertising Appear in Europe?, PHARMTECH.COM (Jan. 7, 2011), http://www.
pharmtech.com/pharmtech/article/articleDetail.jsp?id=702161. See also LEONARD J. WEBER, PROFITS BEFORE
PEOPLE? ETHICAL STANDARDS AND THE MARKETING OF PRESCRIPTION DRUGS 164-66 (2006).
4 Bryan A. Liang & Tim Mackey, Reforming Direct-to-Consumer Advertising, 29 NATURE BIOTECHNOLOGY

397, 397 (2011).
& AMERICAN LIFE PROJECT, THE SHARED SEARCH FOR HEALTH INFORMATION ON THE
INTERNET 2 (June 11, 2009), available at http://pewresearch.org/pubsl1248/americans-look-online-for-health5 PEW INTERNET

information.
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information sought on the Internet comes from the U.S., 7 thus potentially exposing those in
8
Europe to DTC advertising that is otherwise illegal in their country.
The promotion of pharmaceutical products directly to consumers has been highly
contested for over fifteen years. 9 Proponents of such advertising posit that it is beneficial
because it promotes patient participation in their own medical treatment. ' 0 Patients are better
informed about treatment options due to their exposure to pharmaceutical advertising, which
may lead to increased communication with their physicians. t1 That view is reflected in
Rimbert v. Eli Lilly and Co., where the Court opined that informed consumers are more likely
to ask questions of their doctor, potentially increasing a patient's reliance on her doctor's
input.' 2 The Court acknowledged the argument that DTC advertising can lead to a patient
demanding a prescription drug from the physician; 13 however, the Court reasoned that when
there is a more open dialog between patient and physician, the physician is in a better position
to exercise his professional judgment. 14 This is because "[dioctors know more than most that
prescription drugs do not act the same in each person; indeed, because each body is unique,
the drug will not work exactly the same in any two people."' 5 In the Court's view then,
patient reliance on physician input is necessary to receive appropriate care. The Court thought
it illogical that a better-informed doctor/patient relationship could be considered a negative
16
outcome of DTC advertising.
Finally, many advocates assert that DTC advertising encourages people with undertreated conditions to seek help.7 A 2003 study found that a quarter of the people who visited
their doctor as a direct result of DTC advertising were diagnosed with a new condition, and
nearly half of them were described as having a high-priority health problem. 18 When such
conditions are finally treated it not only improves patient health, but also has the potential to
decrease overall costs by avoidance of expensive hospital or surgical interventions which may
6 A 2007 study of seven European countries found that approximately 52% of European adults search for
health information online. Per Egil Kummervold, et al., eHealth Trends in Europe 2005-2007: A PopulationBased Survey, 10 J. MED. INTERNEr RES. e42 (2008), available at http://www.jmir.org12008/4/e42/.
7 See id.

8 Frank Auton, The Patientas Consumer: The Advertising of PharmaceuticalsDirectly to Consumers Should
Be Allowed and Encouraged, ECON. AiF., June 2007, at 64.
9 Frank Auton, Direct-to-Consumer Advertising (DTCA) of Pharmaceuticals: An Updated Review of the
Literature Since 2003, ECON. AFF., Sept. 2006, at 24.
1o John E. Calfee, Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs, 21 J. PUB.
POLICY MKTG. 174, 176-77 (2002).
11 Id.

12 Rimbert v. Eli Lilly and Co., 577 F.Supp.2d 1174, 1219 (D.N.M. 2008).
13 Id. at 1218.
14Id. at 1219.
15 id.
16 Id. at 1221.

17 See Auton, supra note 8, at 69. Undertreated conditions are those that may not have outward symptoms, such
as depression, hypertension or high cholesterol. Id.
18Joel S. Weissman, et al., Consumers' Reports on the Health Effects of Direct-to-ConsumerDrug Advertising,
HEALTH AFF. WEB EXCLUSIVE W3-82, 88 (Feb. 26, 2003), http://content.healthaffairs.org/content/early/2003/
02/26/hlthaff.w3.82.full.pdf+html. The study used the 15 high-priority conditions adopted by the Institute of
Medicine which include: cancer, diabetes, HIV/AIDS, emphysema, high cholesterol, asthma and Alzheimer's
disease, among others. INSTITUTE
THE 21ST CENTURY 91 (2001).
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be required if the condition goes untreated. 19 Additionally, it is thought that informed patients
21
are more likely to comply with treatment,20 which also decreases overall healthcare costs.
In contrast, many critics (often physicians and insurance companies) believe that
DTC advertising puts consumers in the place of doctors who are trained to prescribe the
necessary medications. 22 Indeed, one study found that eighty percent (80%) of physicians
surveyed believe that DTC advertising "encourages patients to seek treatments they do not
need."' 23 Some physicians have reported that DTC advertising may cause a patient to "misperceive a drug's effectiveness . ..and challenge[ ] [a] physicians' influence and authority ....,,24 Moreover, some feel that DTC advertising affects the prescribing habits of doctors
25
by undermining optimal prescribing by encouraging overtreatment of some conditions, as
26
drugs.
well as by driving up the cost of name-brand
Some opponents believe that while DTC advertising may lead to more knowledgeable patients and prompt robust discussion between a patient and his doctor, it is detrimental in
its wider effect on the public health in its current form.2 7 One argument is that DTC advertising has a serious negative effect on public health because the advertisements are presented in
a manner that provokes a consumer's emotional response, in order to further the pharmaceutical industry's goal of selling drugs. 28 Advertising based on emotional appeals may lead consumers to "seek treatment for clinically inappropriate reasons, such as fear, anticipated regret
29
from not using the product, or expectations of happiness if they do use the product.
Bioethicist Leonard J. Weber believes that these types of emotional appeals in DTC advertis19 Auton, supra note 8, at 70. See also Christopher Roebuck, Joshua N. Liberman, Marin Gemmill-Toyama &
Troyen A Brennan, MedicationAdherence Leads to Lower Health Care Use and Costs Despite IncreasedDrug
Spending, 30 HEALTH AFFAIRS 91, 91 (2011).
20 See Angela Coulter, Vikki Entwistle & David Gilbert, Sharing Decisions with Patients: Is the Information
Good Enough?, 318 BRIT. MED. J. 318 (1999).

21 A large study of patients suffering from chronic vascular disease (congestive heart failure, hypertension,
diabetes and dyslipidemia were included in the study) found that the average annual medical spending for each
condition were significantly reduced when patients were compliant with their treatment regimen, due to less
hospitalization of those patients. Those with congestive heart failure saved nearly $9,000, those with
hypertension and diabetes saved over $4,000 each, and those with dyslipidemia saved nearly $2,000 annually.
Roebuck, Liberman, Gemmill-Toyama & Brennan, supra note 19, at 93-97.

22 See Kurt C. Stange, Time to Ban Direct-to-Consumer PrescriptionDrug Marketing, 5 ANNALS FAM. MED.
101, 101 (March/April 2007).

23 Matthew F. Hollon, Direct-to-Consumer Advertising A Haphazard Approach to Health Promotion, 293
JAMA 2030, 2031 (April 27, 2005).

24 Joel S. Weissman, et al., Physicians Report on Patient Encounters Involving Direct-To-Consumer
Advertising, HEALTH Avi. WEB EXCLUSIVE W4-219, 220 (Apr. 28, 2004), http://content.healthaffairs.org/
content/early/2004/04/28/hlthaff.w4.219.full.pdf+html.
25 Hollon, supra note 23, at 2031. But see WEBER, supra note 4, at 147-48, for the proposition that in
healthcare, unlike other types of business, the customer is not always right and healthcare professionals have the
duty to provide recommendations based on "professional standards and expertise" rather than because they want
a certain treatment. Id. at 148.
26 Calfee, supra note 10, at 177.
27 See Stange, supra note 22, at 101. See generally Hollon, supra note 23.
28 Jackie Glatter, Promotion, Information and Advertising: Why Increasingly Blurred Boundaries Do Not
Benefit the Public, I J. GENERIC MEDS. 128, 129-30 (2004). Emotional appeal tactics can include depictions of
loss of control, social approval distress, or endurance, among other depictions. Dominick L. Frosch, et al.,
Creating Demandfor PrescriptionDrugs: A Content Analysis of Television Direct-to-Consumer Advertising,

5

ANNALS FAM. MED. 6, 9-10 (2007).

29 Frosch, supra note 28 at 10.
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30
ing are tantamount to manipulation because they do not rely on any rational persuasion.
Finally, critics also suggest that DTC advertising may have a negative influence on physician/
patient communication in that a physician may spend so much time discussing why an advertised drug the patient requests is not appropriate, that other important conversations regarding
31
the patient's health and treatment do not take place.

Regardless of one's view on DTC advertising, people are now better informed than
ever about their own health issues due to the advent and ever-expanding use of the Internet,
and the various mobile applications and social media that go along with contemporary use of
technology.32 The sheer amount of health information available on the Internet has lead to
much inaccurate, if not outright harmful, information and there is often no way to distinguish
between accurate and inaccurate information without specialized health knowledge 33 or excellent Internet research skills. 34 The Internet poses an obstacle for DTC advertising by pharmaceutical companies in the U.S. because there has not been much guidance from the Food and
Drug Administration ("FDA") relating to its use as an advertising platform, other than that
any advertising on the Internet must comply with the regulations controlling DTC advertising
in any other medium. 35 Members of the U.S. pharmaceutical industry presented possible solutions to the problems relating to promotion of their products on the Internet to the FDA at a
hearing in Washington D.C. in 2009.36 However, the FDA has yet to issue guidance 37 on the
topic, leaving pharmaceutical companies largely in the dark about what is expected of them in
a medium of unlimited time and space, unlike television or print advertising. Despite this lack
of guidance, pharmaceutical manufacturers have attempted to keep their DTC advertising on
the Internet within the bounds of current legislation.
While the European Union ("EU") has confronted the issue of DTC advertising
many times, 38 they consistently refuse to change the law to allow the practice or even to allow
the dissemination on the Internet of neutral, non-promotional information by pharmaceutical
manufacturers about their products. 39 Pharmaceutical companies in the EU, who arguably
know the most about their products and thus are in the best position to disseminate that infor-

30 WEBER,

supra note 3, at 166-69.

31 Stange, supra note 22, at 101.
32 See Calfee, supra note 10, at 176-77.
33 Faisal Hanif, et al., The Role of Quality Tools in Assessing Reliability of the Internetfor Health Information,
34 INFORMATICS FOR HEALTH & SOCIAL CARE 231, 231-34 (2009).

34 Wilfried Honekamp & Herwig Ostermann, Anamneses-Based Internet Information Supply: Can a
Combination of an Expert System and Meta-Search Engine Help Consumers Find the Health Information they
Require?, 4 OPEN MED. INFORMATICS J. 12, 12-13 (2010), available at http://www.ncbi.nlm.nih.gov.ezproxy.

hofstra.edu/pmc/articles/PMC2874219/pdf/TOMINFOJ-4-12.pdf?tool=pmcentrez.
35 Bryan A. Liang & Timothy Mackey, Direct-to-Consumer Advertising with Interactive Internet Media:
Global Regulation and Public Health Issues, 305 JAMA 824, 824 (2011).
36 See generally Public Hearing on Promotion of FDA-Regulated Medical Products Using the Internet and
Social Media Tools, FOOD & DRUG ADMIN. (Nov. 12, 2009) [hereinafter "Public Hearing on Promotion of
FDA-Regulated Medical Products"] (transcript available at http://www.fda.gov/downloads/AboutFDA/Centers
Offices/OfficeofMedicalProductsandTobacco/CDER/JCM 193462.pdf).
37 FDA guidance documents are non-binding but reflect the agency's "current thinking on a particular subject."
Guidances (Drugs), FOOD & DRUG ADMIN. (Feb. 9, 2012), http://www.fda.gov/drugs/guidancecompliance
regulatoryinformation/guidances/default.htm. Other approaches can be used so long as they adhere to the
appropriate statute and regulations. Id.
38 Auton, supra note 9, at 24.
39 Id.
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mation, are left out of the discussion with patients completely, a point of view that the EU
40
recognizes as important, but consistently fails to act upon.
It is likely that both the proponents and critics of DTC advertising have at least a few
valid points. However, simply due to the sheer amount of information available on the Internet, it effectively does not matter whether one believes DTC advertising is "good" or "bad",
since its widespread use guarantees that people are going to get the information they seek. It is
better for consumers to at least have the option to get the majority of their information from
companies whose Internet presence is highly regulated, and thus likely to be accurate, rather
than from unregulated sources which may contain inaccurate and biased information.
DTC advertising on the Internet can be an opportunity to educate patients and consumers about their health condition and possible treatment options but it cannot effectively be
done without guidance from regulatory authorities in the U.S. and the EU. It is imperative that
the FDA issue guidance documents to the U.S. pharmaceutical industry in a timely manner, as
lack of clarity thus far has lead to pharmaceutical companies falling afoul of current regulations. Equally important, the EU should take seriously the amount of misleading and harmful
health information available on the Internet and allow pharmaceutical companies to become
involved in the education of EU citizens through dissemination of accurate information about
their products, whether through limited DTC advertising or other means.
Section II of this note discusses the history of government regulation of DTC advertising in the U.S. and the EU. Section III gives an overview of the problems the Internet
presents to pharmaceutical manufacturers in both regions. Finally, section IV offers suggestions for the standardization of DTC advertising of pharmaceutical products on the Internet, in
order to improve access to fair and balanced information about such products.
II.

BACKGROUND

Pharmaceutical companies in the United States were marketing their products to
consumers long before the government began regulating direct-to-consumer (DTC) advertising.' Such advertising initially consisted of promotion of a particular company, without mentioning the products they manufactured. 2 In time, pharmaceutical companies began to
43
engineer advertisements about particular drugs that were directed specifically at consumers.
At the same time, the FDA began requiring that patient package inserts be included with
certain medications, to instruct the patient in their proper use, a44 or to inform the patient about
the risks of the drug.5 5 The first explicit DTC advertisements of pharmaceuticals in the early
1980s' 6 prompted the FDA to promulgate guidelines for pharmaceutical companies who
wished to advertise to the public.4 7 Those initial guidelines focused on providing a substantial
40 See Robert Geyer, The Politics of EU Health Policy and the Case of Direct-to-ConsumerAdvertising for

Prescription Drugs, 13 J. ADVER. 586, 596 (2011).
41 Jeremy A. Greene & David Herzberg, Hidden in Plain Sight: Marketing Prescription Drugs to Consumers in
the Twentieth Century, 100 Am. J. PUB. HEALTH 793, 794-96 (2010).
42 Id. at 795.

41 Id. at 796-97.
44 Wayne L. Pines, A History and Perspective on Direct-to-Consumer Promotion, 54 Food & Drug L. J. 489,
489-90 (1999).
45 Id. at 490.
46 Id. at 491.
41 Id. at 493.
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amount of risk information in the advertisements. 48 Unfortunately for pharmaceutical companies, the amount of risk information the FDA required was difficult to fit into a short television commercial, which lead to advertisements that did not give enough information to require
the summary of risk information. 49 Because of the confusion caused by vague advertisements,
the FDA liberalized regulation of DTC advertising of product-specific pharmaceutical products in broadcast media in 1997. 5 0 The increasing prominence of Internet use has changed the
way companies advertise to consumers, and pharmaceutical manufacturers in the U.S. are no
51
exception.
52
In contrast, the EU has remained steadfast in its opposition to DTC advertising
although it is currently considering allowing European pharmaceutical companies to distribute
non-promotional information on the Internet about their products to consumers. 53 This section
looks at the history and development of DTC advertising regulations in the U.S. and the EU.
A.

The History of Direct-to-Consumer Advertising in the United States

Pharmaceutical companies in the U.S. have an abundant and solid regulatory framework to which their DTC advertising must conform. 54 This framework has developed over
many years of case law and incremental regulation, at least somewhat preparing the industry
for the advent of the widespread advertising medium of the Internet. Prescription drug consumers have access to almost limitless information on medical conditions and the drugs that
treat them through the Internet, and it is used extensively for that purpose. 55 The impact of
free access to limitless information is that patients are becoming informed consumers of pharmaceutical products, and advocates for specific aspects of their medical care, rather than rely56
ing solely on their physicians' expertise when it comes to their own health care.
When the FDA first began formally regulating DTC advertising, its main focus was
assuring that pharmaceutical companies complied with the brief summary requirement, 57 as
58
mandated by the Federal Food, Drug, and Cosmetic Act. Regulation of DTC advertising
id.
49 Green & Herzberg, supra note 41, at 799-800.
50 Pines, supra note 44, at 495.
51 Pharmaceutical companies in the late 1990s used websites to disperse information in both educational and
48

humorous ways through cartoons and graphics, as well as trendy themes. See Nancy K. Plant, Prescription
Drug Promotion on the Internet: Tool for the Inquisitive or Trap for the Unwary?, 42 ST. Louis. U. L.J. 89,
104-07 (1998).
52 See generally Gayer, supra note 40, for a history of EU policy on DTC advertisting.
53 David Barratt, Image Makeover: Europe Can Benefitfrom the US Experience of the DTC Advertising Model,
PMLIVE.coM, 51, (May/June 2010), http://www.eaca.be/hcc/Mayjune-2010-Image-makeover.pdf.
M See generally 21 C.F.R. § 202.1 (2011) (Federal DTC advertising regulations).
55 See Plant, supra note 51, at 104-07; James M. Wood & Howard L. Dorfman, "Dot.Com Medicine" Labeling in an Internet Age, 56 FOOD & DRUG L.J. 143, 143-44 (2001).
56 Anthony N. DeMaria, The Commercial Promotion of Medicine, 40 J. AM. C. CARDIOLOGY 2060, 2060
(2002).
57 Lance S. Gilgore, A Considerationof Direct-to-ConsumerAdvertising of PrescriptionDrugs and Potential
Legal Problems with the Brief Summary Requirement: Is the FDA's Regulatory Authority Illusory?, 46 FOOD
DRUG CosM. L.J. 849, 850-51 (1991). The brief summary requires a statement of the side effects,
contraindications, and effectiveness of the advertised pharmaceutical product. 21 U.S.C. § 352(n). It was
initially intended to reduce the promulgation of false or misleading information about pharmaceuticals to
physicians. It was adopted in its original form for application to DTC advertising. Gilgore, supra, at 850-51.
5' See 21 U.S.C. § 352(n).

http://scholarlycommons.law.hofstra.edu/jibl/vol11/iss2/9

6

West: National Marketing Gone Unintentionally Global: Direct-to-Consume
NATIONAL MARKETING GONE UNINTENTIONALLY GLOBAL

59
The doctrine
arose against the backdrop of the tort doctrine of the learned intermediary.
posits that because the physician is a "learned intermediary" between the pharmaceutical company and the patient, the physician (as the prescriber of the drug) is in the best position to
fully understand the risks and benefits of a particular drug for a particular patient, and is thus
60
most capable to disseminate that information to the patient. Thus, according to the doctrine,
pharmaceutical companies must only warn the physician of the risks of a prescription drug in
6
order to avoid liability. '
This rule was challenged with the development of the birth control pill. In the
landmark Massachusetts case of MacDonald v. Ortho PharmaceuticalCorp., the court ruled
that oral contraceptives "bear peculiar characteristics" which require an exception to the
learned intermediary rule. 62 The court opined that "[w]hereas a patient's involvement in decision-making concerning use of a prescription drug to treat a malady is typically minimal or
nonexistent[,]" the pill is not prescribed to fix a medical problem, but is given to young,
healthy females electively, allowing the patient to have a more active role in choosing which
form of birth control she will use.6 3 This thus "relegat[es] the prescribing physician... to a
relatively passive role." 64 Moreover, when a woman is prescribed oral contraceptives, it is
usually during an annual appointment and she receives a prescription for the entire year, thus
the physician's ability to monitor the patient is further limited. 65 For these reasons, the court
ultimately held that in the case of oral contraceptives the manufacturer has a duty to warn the
patient of directly.' Thus, pharmaceutical manufacturers now have a duty to directly warn
patients of the risks of certain drugs when their purpose is primarily preventative. 67 For other
types of medications, pharmaceutical companies have no duty to warn patients directly of the
risks associated with that medication. 68 MacDonald, along with a general increase in patient
demand for access to health information, is purported to have had a large impact on the FDA's
relaxation of regulations relating to DTC advertising. 69 Arguably, DTC advertising has an
impact similar to that of oral contraceptives on a patient's self-involvement in her own health
care decisions. Patients who see an advertisement and recognize their own symptoms or risk
factors may then contact their physician to discuss their treatment options, thus participating

59 RESTATEMENT (THIRD) OF TORTS: PROD. LiAB. § 6 (1998).
60 Id.
61 Id. at cmt. e.
62 MacDonald v. Ortho Pharm. Corp., 475 N.E.2d 65, 69 (1985).
63 Id.
64 Id.
65 Id. at 70.
66 Id. This is done in the form of patient package inserts. Id.
67 This requirement has consistently been limited to prescription contraceptives and "vaccinations in clinics
where mass inoculations are performed." This is because in that type of environment each patient is generally
not evaluated thoroughly prior to administration of the drug. Additionally the argument has been advanced that
pharmaceutical manufacturers should be held to the same standard when the product has been advertised in
mass media. RESTATEMENT (THIRD) OF TORTS: PROD. LIAB. § 6 cmt. e (1998).
68 Id.

69 The general public's interest in health and medication related information began to flourish as more
information became available. In the 1960s and 1970s the FDA began requiring more and more drugs to be
given with a patient package insert to inform patients of the potential risks of the product. In the 1980s, books
that had previously only been available to physicians began to pop up in regular consumer bookstores. The
medical community began to realize that consumers were playing a larger role in health care decisions and
when the first paid advertising directed at consumers was issued, though not in the form we generally see today,
the FDA began to discuss the implications of paid advertising. See Pines, supra note 44, at 489-91.
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more fully in their own medical care. 70 Pharmaceutical manufacturers rely on patients' desire
to participate in treatment decisions when they spend billions of dollars on DTC advertising
7
per year. '
The FDA first claimed jurisdiction over DTC advertising in 1985 after requesting a
voluntary moratorium resulting from two highly visible DTC advertisements in 1981 which
concerned the FDA and caused it to address DTC advertising for the first time.72 The FDA
determined that the standards of "fair balance" 73 and "brief summary" 74 would "provide
75
American consumers with an adequate safeguard from deceptive or misleading claims."
Because the "brief summary" required was anything but brief, DTC advertising was effectively limited to print media, where the summary of risk information could be disseminated in
fine print. 76 Broadcast advertising was thus limited to "help-seeking" 77 or "reminder"78 type
advertisements. 79 Although DTC advertising was never illegal, 80 drug companies were generally wary of it because it was considered unethical to market directly to consumers. 8t Additionally, the requirement of an "adequate provision" made for "information in brief summary
82
relating to side effects, contraindications, and effectiveness" was confusing and vague.
The FDA relaxed the rules of DTC advertising when it issued draft guidance in 1997
explicitly permitting television advertising of specific products for the first time. 83 The guidance, which was finalized in 1999, clarified the ways in which the "adequate provision"
could be fulfilled in broadcast advertisements. 84 The guidance called for the presentation of a
brief summary of all of the risks of the advertised drug 85 or, alternatively, to provide for the
dissemination of the approved package labeling through one of four avenues: 1) disclosure of
70 Alan F. Holmer, Direct-to-ConsumerPrescriptionDrug Advertising Builds Bridges Between Patients and
Physicians, 281 JAMA 380 (1999).
71 See WEBER, supra note 3, at 166-69.
72 Greene & Herzberg, supra note 41, at 799.
73The fair balance requirement is fulfilled when the treatment of risk and benefit information provided in the
advertisement are equally thorough and complete throughout the piece. 21 C.F.R. § 202.1(e)(5)(ii) (2008).

74"The 'brief summary' includes all the risk information about a prescription drug and is generally based on
the prescribing information. [It] may leave out non-risk information, such as the chemical description of the
drug, how it works in the body, and directions for using it. For DTC ads, we recommend that brief sunmaries
be written in language that consumers can understand." PrescriptionDrug Advertising: Questions and Answers,
FOOD & DRUG ADMIN. (June 23, 2009), http://www.fda.gov/Drugs/ResourcesForYou/Consumers/Prescription

DrugAdvertising/UCM076768.htm#riskinformation.
75 Greene & Herzberg, supra note 41, at 799.
76 id.
77 Help-seeking advertisements mention information (often simply that treatments are available) about a
specific condition and encourage consumers to speak to their doctor. The ads may mention a drug manufacturer
but not a particular drug or product, otherwise they would be subject to the "brief summary" requirement.

Tamer Nordenburg, Direct to You: TV Drug Ads that Make Sense, 32 FDA CONSUMER 7 (1998).
78 Reminder advertisements mention the name of the drug, but not the condition for which it is indicated. This
also avoids the need for the "brief summary" requirement, but can lead to some confusion. id.
79 Greene & Herzberg, supra note 41, at 799-800.
80 Auton, supra note 8, at 65.
81 See Greene & Herzberg, supra note 41, at 793.
82 Meredith B. Rosenthal, Ernst R. Berndt, Julie M. Donohue, Richard G. Frank & Arnold M. Epstein,
Promotion of PrescriptionDrugs to Consumers, 346 NEW ENG. J. MED.498, 498 (2002).
83 Pines, supra note 44, at 496.
84 Rosenthal, Bemdt, Donohue, Frank & Epstein, supra note 82, at 498-99.
85 FOOD & DRUG ADMIN.,

GUIDANCE FOR INDUSTRY: CONSUMER-DIRECTED BROADCAST ADVERTISEMENTS

1

(1999).
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a toll-free telephone number that consumers could call to request the package labeling information either through the mail, or read to them over the phone; 2) reference to a similar print
advertisement that contained the brief summary of risk information; 3) a web address where
the information could be located; or 4) a reference that more information could be learned
from their health care provider. 86 Even while the FDA has stringent guidelines for DTC advertising, pharmaceutical manufacturers are not required to get approvalfrom the FDA prior
to broadcasting the advertisements, only to submit their advertising materials prior to broadcast. 87 The FDA reviews only a small percentage of the materials it receives and often doesn't
send regulatory letters until long after the advertisement has been broadcast. 88 Thus, the prac90
89
and the industry is happy to comply.
tice is essentially self-regulated by the industry
Penalties are very rarely necessary because pharmaceutical companies are reluctant to fall
afoul of the very agency that has the power to grant their products regulatory approval. 9 1
In 1999, the New Jersey Supreme Court stated in Perez v. Wyeth Labs., Inc. that
DTC advertising so profoundly impacts patients that "consumers are active participants in
their health care decisions, invalidating the concept that it is the doctor, not the patient, who
decides whether a drug or device should be used." 92 Drug companies in New Jersey enjoy a
rebuttable presumption that they are not liable for damages resulting from defective pharmaceutical products so long as they adhere to FDA DTC advertising guidelines, but that fact does
not free manufacturers from liability in an instance where "misinformation was a substantial
' 93
factor contributing to [a patient's] use of a defective pharmaceutical product.
Perez demonstrated to pharmaceutical companies the importance of adhering to the
FDA's regulations regarding DTC advertising. The plaintiffs in Perez asserted that the defendant, Wyeth, began advertising its surgically implantable contraceptive Norplant in 199194
without including a specific warning that the product could cause pain and scarring upon
removal, among other side effects.95 The plaintiffs further contended that there had been
studies published in medical journals that indicated that Norplant had a high incidence of
complication during removal. 96 Wyeth argued that it should not be liable for the patients'
injuries because of the learned intermediary doctrine, 97 as Norplant is not an oral contracep86 Id. at 2-4.

87 Liang & Mackey, supra note 4, at 398.
88 Id.
89 id.
90 Calfee, supra note 10, at 175.
91 Id.

92 Perez v. Wyeth Labs. Inc., 734 A.2d 1245, 1256 (N.J. 1999).
9' Id. at 1263.

94 This was prior to the FDA's relaxation of restrictions on DTC advertising, and before DTC advertising
became widely utilized in 1997. At the time of the Norplant print advertisements the FDA required that
advertisements had to meet the same requirements as those directed at doctors: they had to be "fairly balanced"
and must include a "brief summary" of the risks of the drug. Additionally, all other FDA regulations must be
followed. Because the "brief summary" requirement was considered cumbersome (it is not "brief' at all), most
companies created advertisements that did not direct consumers to a specific product, but detailed symptoms
and encouraged them to see their doctor. Another type of "help-seeking" advertisement mentioned the name of
a drug, without mentioning its purpose. See Pines, supra note 44, at 493-94.
95 Perez, 734 A.2d at 1248.
96 One study found that "fifty two percent of physicians reported complications during removal." Id. at 1256.
9' id. at 1248-49.
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tive which would require direct warning from the manufacturer to the patient.98 The Court
came to the conclusion that pharmaceutical manufacturers who advertise directly to consumers are not automatically relieved of liability even if they comply with the requirement of
warning the physician under the learned intermediary doctrine. 99 "The direct marketing of
drugs to consumers generates a corresponding duty requiring manufacturers to warn of defects
in the product.'l ° ° Currently, New Jersey is the only state that maintains this position, while
forty-four states adhere to the traditional learned intermediary doctrine in prescription drug
cases."10 It is against this backdrop that the current FDA regulations have developed, and are
continuing to be developed.
The FDA's current DTC advertising regulations are housed in the Code of Federal
Regulations at 21 C.F.R. § 202(1) (2011). The most important of these regulations, for the
purposes of this Note, is undoubtedly the "brief summary" requirement. This provision requires a brief and true statement of the side effects, contraindications, and effectiveness of the
advertised medication.' 0 2 The requirement is not satisfied if the statement presented is (a)
false or misleading with respect to side effects, contraindications, and effectiveness; (b) does
not present a fair balance between the effectiveness information and the side effect/contraindication information; or (c) there is a failure to reveal material facts about the consequences of
10 3
taking the advertised medication.
Of the thirty-one warning letters sent by the Office of Prescription Drug Promotion
("OPDP") (formerly the Division of Drug Marketing, Advertising, and Communications "DDMAC") in 2011, the majority fell into the categories of false/misleading or failure to
present balanced information with respect to side effects, contraindications, and effectiveness." ° The warning letters indicated diverse promotional methods including websites,
brochures, videos, and both physician-directed and consumer-directed print ads, among other
methods.' 0 5 Most issues of misleading promotion in the Internet materials related to the
06
placement of risk information and/or lack of prominence of such information.'
98 Cf. MacDonald v. Ortho Pharm. Corp., 475 N.E.2d 65 (1985) (holding that oral contraceptives are an
exception to the learned intermediary doctrine due the relatively passive role of the physician in the selection
and monitoring of oral contraceptive consumption).
99 Perez 734 A.2d, at 1262-64. Recall that the learned intermediary rule absolves pharmaceutical manufacturers
of any liability toward patients so long as the information provided to the physician complied with FDA
standards. See RESTATEMENT (THIRD) OF TORTS: PROD. LIAB. § 6 cmt. b (1998).
10o Perez 734 A.2d, at 1263.
1o1Thom v. Bristol-Myers Squibb Co., 353 F.3d 848, 852 (10th Cir. 2003).
102 21 C.F.R. § 202(l)(e)(1) (2011).
103 Id. § 202(1)(e)(5)(i)-(iii).
104 See Warning Letters 2011, FOOD & DRUG ADMIN., available at http://www.fda.gov/Drugs/Guidance

ComplianceRegulatorylnformation/En forcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetters
toPharmaceuticalCompanies/ucm238583.htm. At least fifteen cited either minimization of risk information or
omission of risk information, or both, as a reason the product was considered "misbranded". Risk information
was mentioned thirty times overall. Unsubstantiated claims (including claims of superiority, safety, and/or
efficacy) were mentioned thirteen times, and overstatement of efficacy was mentioned eleven times. Other
issues, totaling twenty mentions, included promotion of unapproved use (two), inadequate communication of
indication (four), omission of material facts (four), promotion of unapproved/investigational products (three),
promotion of broadened indication (four), and misleading patient compliance claims (one). Id.
See id.
106 See id. One letter, to Cephalon, Inc., regarding its healthcare professional website for the drug "Trisenox"
described misleading promotion due to an unfair balance of information. "Promotional materials are misleading
if they fail to present information related to side effects and contraindications with a prominence and readability
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Seven, or approximately twenty-three percent, of the 2011 warning letters related to
promotion on the Internet. 10 7 This is slightly less than in 2010, when fifty-one warning letters
10 8
and
were sent, with fifteen, approximately twenty-nine percent, of them Internet related
2009, when approximately forty-four percent of the DDMAC warning letters related to Internet promotion. 1° 9 The decrease in Internet promotion related warning letters does not necessarily mean that manufacturers are getting better at discerning what the FDA expects from
this type of promotion. Rather, it appears to be due to manufacturers relying more on helpseeking and reminder type sponsored links in order to avoid the brief summary
requirement. 1 10
Although the U.S. has been regulating DTC Advertising for many years now, the
flexibility and ever-changing nature of the Internet requires that some regulations be
rethought. Some may not require much change; however, the FDA should address the unique
nature of the Internet as an advertising platform so that pharmaceutical companies know what
is expected of them. Unlike the U.S., the EU has traditionally provided significantly less
commentary on the topic of DTC advertising, other than consistently rejecting proposals to
111
allow the practice.
B.

The History of Regulation of Direct-to-Consumer Advertising in Europe

The European Union Community Code relating to medicinal products for human use
strictly forbids the advertising of medicinal products to the general public, and even to physicians, if those products are only available by prescription or contain psychotropic or narcotic
substances. "12 The Directive defines advertising of medicinal products as including "any form
of door-to-door information, canvassing activity or inducement designed to promote the prereasonably comparable with the presentation of information on the effectiveness of the drug, taking into account
all implementing factors such as typography, layout, contrast, headlines, paragraphing, white space, and any
other techniques apt to achieve this emphasis." Letter from Karen Rulli, Group Leader, Div. of Drug Mktg.,
Adver., and Commcn's, Food & Drug Admin., to Franklin Vairinhos, Dir., Regulatory Affairs, Cephalon, Inc.
(June 21, 2011), available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticaI
CompaniesIUCM260575.pdf.
See Warning Letters 2011, supra note 104.
108 See Warning Letters 2010, FoOD & DRUG ADMIN., available at http://www.fda.gov/Drugs/Guidance
107

ComplianceRegulatorylnformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetters
toPharmaceuticalCompanies/ucm 197224.htm.
109 See Warning Letters 2009, FooD & DRUG ADMIN., available at http://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetters
toPharmaceuticalCompanies/ucm055773.htm.
110 Google found that the click-through rate (the number of times an advertisement was clicked on by a user,
divided by the number of times the advertisement was displayed) of sponsored advertisements decreased
significantly after the FDA issued warning letters stating that having the risk information "one click away" was
unacceptable. Google attributed that decrease to less clarity, and thus less utility for users, of help-seeking and
reminder advertisements. Amy Cowan, Head of Indus., Google, Public Hearing on Promotion of FDARegulated Medical Products Using the Internet and Social Media Tools, Foot & DRUG ADMIN., (Nov. 12,
2009), at 438-40, (transcript available at http:/www.fda.gov/downloads/AboutFDA/CentersOffices/Officeof
MedicalProductsandTobacco/CDERIUCM 193462.pdf).
I1 See Geyer, supra note 40, at 590-97.
112 Council Directive 2001/83/EC, art. 88, 2001 O.J. (L 311) 67, 92, as amended by Council Directive 2004/27/
EC, O.J. (L 136) 34.
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scription, supply, sale or consumption of medicinal products; it shall include in particular: the advertising of medicinal products to the public ..
113 The drug's label and accompany14
ing package insert do not fall into the category of advertising.'
Since 1998 there have been many attempts by proponents of DTC advertising to
convince the EU to loosen its stance on the practice, to little avail.1 15 In the year after the
restrictions on DTC advertising were liberalized in the U.S., members of the industry and the
EU Commission published a report claiming that the difference in DTC advertising regula116
tions in the U.S. and EU created a problem for the transatlantic pharmaceutical industry.
They posited that the ban was unfair to citizens in the EU who want information about
pharmaceuticals, and was behind the technological curve.' 17 At least partly in response to that
report, an EU task force was created to review policy concerning DTC advertising.' 18 The
task force "began pushing for a new debate" on DTC advertising with a bent toward allowing
1
pharmaceutical manufacturers to provide educational information to consumers. 19
That, in turn, led to the first real attempt at changing EU policy in 2001, when a
member of the European Commission ("EC") proposed that pharmaceutical companies be
allowed to "communicate information about drugs for asthma, diabetes and Aids [sic] directly
to the public within 'disease awareness' campaigns."12 0 Although the Commissioner assured
that the goal was not to allow DTC advertising, 12 1 the proposal was soundly rejected by the
European Parliament, which felt that approval would "let the genie out of the bottle, bringing
a U.S. scenario to Europe."'122 The EC reconsidered its stance on DTC advertising once again
in 2007.123 Although it eventually maintained that the ban on DTC advertising should remain
in force, 124 it acknowledged that "the pharmaceutical industry possesses the key information
on their medicines but this information can currently not be made available to patients and
healthcare professionals throughout the EU. ' 125 The Commission ultimately suggested that
26
the difference between information and advertising should be further distinguished.'
In December of 2008, the Commission submitted a proposal for amendments to both
the EC Directives and Regulations which would allow for the distribution of non-promotional
"' Id. at 91.
114 Id. at 92.
115 See Geyer, supra note 40, at 590-97.
116

Id.at 593.

117 id.
118

Id.at 594.

119 Id.

120 Auton, supra note 9, at 29. See also Geyer, supra note 40, at 594.
121Geyer, supra note 40, at 595.
122 id.

123 Id. at 596.
124 Communicationfrom the Commission to the European Parliamentand the Council Concerning the Report
on Current Practicewith Regard to Provision of Information to Patients on Medicinal Products, at 10, COM

(2007) 862 final (Dec. 20, 2007), available at http://ec.europa.eu/health/human-use/information-to-patient/
legislative-developmentsen.htm.
125 Id. at 9. Presumably the Commission meant that patients and healthcare professionals cannot get
information other than the label and package insert information directly from the pharmaceutical company. It is
also possible that they meant that the information cannot be accessed over the Internet. The Communication is
not clear. See generally id. at 9-10.
126 Id. at 9-10.
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information by pharmaceutical companies to the public.'
stated thus:

27

The aim of the proposals was

Provide for a clear framework for provision of information by marketing
authorisation holders about their prescription-only medicines to the general
public with a view to enhancing the rational use of these medicines, while
ensuring that the legislative framework continues to prohibit direct-to-con28
sumer advertising of prescription-only medicines.'
129
Although the Commission had no interest in raising the ban on DTC advertising,
it did strongly suggest that both the Regulation and Directive be altered to include a provision
for dissemination of certain types of pre-approved consumer-directed information.130 Specifically, it encouraged distribution of information "about non-interventional scientific studies, or
accompanying measures to prevention and medical treatment, or information which presents
the medicinal product in the context of the condition to be prevented or treated.-' 3 ' The
proposed Directive specifically excludes television or radio as a medium for the distribution
of this information, but would allow for distribution through medically related journals and
Internet websites. t32 The Directive was once again rejected by the Employment, Social Policy, Health and Consumer Affairs Council, which called for further "in-depth reflection" and
requested that the Commission prepare a "'thorough report' of the impact of future
1 33
measures."

In 2010, the European Parliament approved an amended version of the previous
proposal that would allow pharmaceutical companies to make limited information available to

127 See Proposalfor a Directive of the European Parliament and of the Council Amending, as Regards
Information to the General Public on Medicinal Products Subject to Medical Prescription, Directive 2001/83/

EC on the Community Code Relating to Medicinal Productsfor Human Use, COM (2008) 663 final (Dec. 10,
2008) [hereinafter Proposalfor a Directive, COM (2008) 663], available at http://eur-lex.europa.eu/LexUri
Serv/LexUriServ.do?uri=COM:2008:0663:FIN:en:PDF; Proposalfor a Regulation of the European Parliament

and of the Council Amending, as Regards Information to the General Public on Medicinal Productsfor Human
Use Subject to Medical Prescription,Regulation (EC) No 726/2004 Laying Down Community Proceduresfor
the Authorisation and Supervision of Medicinal Productsfor Human and Veterinary Use and Establishing a

European Medicines Agency, COM (2008) 662 final (Dec. 10, 2008) [hereinafter Proposalfor a Regulation,
COM (2008) 662], available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2008:0662:FIN:

en:PDF.
128See Proposalfor a Directive, COM (2008) 663, supra note 127, at 2; Proposalfor a Regulation, COM
(2008) 662, supra note 127, at 2.
129 In preparation for the proposals, the Commission sought public consultation on the topic of DTC
advertising versus the need for consumer information. The vast majority of respondents indicated that the ban
on DTC advertising should be maintained. European Commission, Summary of the Public Consultation
Responses, at 2, (May 22, 2008), available at http://ec.europa.eu/health/files/patients/docs/summary-publ_
cons_220508_en.pdf.
130 See, e.g., Proposalfor a Directive, COM (2008) 663. supra note 127, at 6.
1I1Id.at 13.

132 Id.at 13-14. The only significant changes offered in the proposed Regulation are a provision for the
dissemination of information on medicinal products to the general public and regulations pertaining to oversight
of the information, which is why it is not discussed at length here. See generally Proposalfor a Regulation,
COM (2008) 662, supra note 127.
133 Geyer, supra note 40, at 597.
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consumers. 134 The EC approved a revised proposal late in 2011, and it has now been passed
on to the European Parliament and Council of Ministers for further debate before final approval. 135 While the proposal extends the ban on DTC advertising to print advertisements, it
allows pharmaceutical companies to provide objective information when it is requested by
patients. 136 The proposal requires that the information be pre-approved by the competent
authorities of the Member States and leaves no room for industry self-regulation, as it does in
the U.S.137 Similar to the FDA's "adequate provision" requirement,1 38 the proposed Directive
requires that contact information for the competent authority, as well as "a statement containing a reference to the most recent package leaflet or an indication as to where that text can be
found," be included with the information. 139 With respect to Internet websites, the proposal
requires that the information available to consumers comply with the Directive.140 Additionally, pharmaceutical companies will be required to link their website to that of the recentlycreated European medicines web-portal, which contains information on pharmaceuticals available in the EU. 141
Although the proposal has not yet been made law, it appears that the EU is finally
taking a step towards providing more comprehensive information about pharmaceuticals to
their citizens. It is an especially important step for a community such as the EU, where Member States do not all share the same language. 142 This Directive, if passed, will allow patients
in Member States to receive the information they seek in their native language, which is
currently not the case because many, if not most, seekers of health information on the Internet
43
in the EU turn to U.S.-based information.1
III.

THE PROBLEM OF THE INTERNET

With the increased use of the Internet in the late 1990s, the FDA contemplated the
impact of that development on the existing DTC advertising regulations. 1" They have been
slow to issue much guidance on Internet promotion in part for fear that it will impinge on the
134 Lynne Taylor, MEPs Vote for Pharma to "Inform not Advertise", PHARMATIMES ONLINE (Nov. 26, 2010),
http://www.pharmatimes.com/Article/10-11-26/MEPs.votefor _pharma to_"informnot-advertise".aspx.
135Press Release, European Commission, Empowering the Patient: European Commission Wants Clearer
Rules for Information on Prescription Medicines (Oct. 11, 2011), available at http://ec.europa.eu/health/files/
patients/ip_ 10-2011/i 11_71 en.pdf.
136 Amended Proposalfor a Directive of the European Parliament and of the Council Amending Directive
2001/83/EC, at 6, COM (2011) 633 final (Oct. 11, 2011) [hereinafter Amended ProposalCOM (2011) 663].
137Id. But c.f.Liang & Mackey, supra note 4, at 398 (proposing that pharmaceutical advertising in the U.S. is
largely self-regulated).
138 See discussion supra Part H.A.
139Amended Proposal COM (2011) 633, supra note 136.
'40 Id. at 7-8.
141 Id. at 8. See also Regulation 1235/2010, of the European Parliament and of the Council of 15 December
2010 Amending, as Regards Pharmacovigilance of Medicinal Products for Human use, Regulation (EC) 726/
2004 Laying Down Community Procedures for the Authorisation and Supervision of Medicinal Products for
Human and Veterinary use and Establishing a European Medicines Agency, and Regulation (EC) 1394/2007 on
Advanced Therapy Medicinal Products, 2010 O.J. (L 348) 10.
142 When a country joins the EU, they select one of their national languages to be an official language of the
EU. There are currently 23 official languages in the EU. Official EU Languages, EUR. COMM. (Feb. 7, 2012),
http://ec.europa.eulanguages/languages-of-europe/eu-languages-en.htm.
143 Barran, supra note 53, at 51.
144See Plant, supra note 51, at 108-10.
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free speech protections of the First Amendment.1 45 Thus, the only guidance the FDA has
provided is that websites promoting prescription drugs and any paid advertising on the Internet must comply with current DTC advertising regulations as they relate to print or broad1 46
cast advertisements.
According to a 2009 Pew Research study, eighty-three percent (83%) of Internet
users look to the Internet when seeking health information. 1 47 Of those, forty-five percent
(45%) look for information about prescription or over-the-counter drugs. 148 About sixty percent (60%) of those seeking health information online look to user-generated content such as
blogs or health-related social media, rather than industry-generated content. 149 The vast majority found the information only somewhat helpful or not helpful at all.1 5 ° Thus, because of
the high percentage of Internet users seeking health information online there is a need for
more accurate and helpful information on the Internet, the regulation of which is a necessary
step to improving quality.
The Internet is equally powerful and problematic for drug companies and regulators
alike, both in the U.S. and the EU because the sheer volume of information available on the
Internet is a reality, as is the potential for misleading or inaccurate information, regardless of
its nature. Additionally, Internet use is becoming more interactive and consumers no longer
just look at information on the Internet, they are now able to participate in the conversation.1 5 1 While the stakes may not be so high when one is simply searching for information
about their favorite celebrity or reading news stories from various sites, when it comes to
health information, accuracy is of the highest importance, because incorrect information carries the potential for adverse effects on both individual and public health. 152 The following
section explores how the U.S. and the EU have addressed, or are attempting to address, DTC
advertising specifically as it relates to the unique challenges the Internet poses.
A.

How DTC Advertising on the Internet Has Been Addressed in the United States

In September 2009, the FDA began soliciting comments from interested parties that
would address the issues of control of, and liability for, information about regulated medical
products posted on the Internet, among several other issues. 153 The FDA inquired as to how
154
the public, members of the industry, and health care providers thought that blogs,
158
56
video sharing, 157 social networks and online communities,
microblogs, 155 podcasts,'
145 Auton, supra note 8, at 66.
146 See generally Warning Letters and Notice of Violation Letters to Pharmaceutical Companies, FoOD &
DRUo ADMIN.
(Jan. 29, 2012), http://www.fda.gov/Drugs/GuidanceComplianceRegulatorylnformation/

EniforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/default.
htm.
147 Pew Internet & American Life Project, supra note 5, at 11.
148 id.
149 Id. at 3.

150 Id.at 20.

151Liang & Mackey, supra note 35, at 824.
152 See id. at 825.

153 Notice of Public Hearing, 74 Fed. Reg. 48083 (Sept. 21, 2009).
154 Web logs, or "blogs," are generally informal journal-type updates that often encourage dialog about the
subject matter. Id. at 48085.
155 A "microblog" is similar to a blog but much shorter. Twitter is a microblog service. Id.
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widgets, 159 and wikis 1 60 could be used to promote regulated medical products "in a truthful,
nonmisleading, and balanced manner."' 6 1 The FDA requested feedback on several key issues,
including liability for online content, the posting of corrective information, fulfillment of regulatory requirements in limited space, and the appropriate use of links. 162 In November 2009,
the FDA held a public hearing on promotion of FDA-regulated medical products using the
Internet and social media tools, where many people gave short presentations addressing the
FDA's concerns.1 63 The presenters included pharmaceutical manufacturers, Internet market64
ing groups, health care advocacy groups, and health care bloggers, among others.'
One concern brought out at the public hearing relates to liability of pharmaceutical
manufacturer and their responsibility for misinformation by third parties on pharmaceutical
company controlled or influenced websites.1 65 For example, the introduction of Google's
"Sidewiki" application made it possible for anybody viewing a website to comment on it in a
16 6
sidebar, and left no control over the content of the Sidewiki to the owner of the site.
Although site owners could claim the first comment position so that it was always the first
post Sidewiki users saw, a representative for Eli Lilly states that the company decided to
refuse the spot because they were unsure if it would open them up to liability for the rest of
the Sidewiki content, including off-label information, 167 which they could not correct and had
168
no control over.

156 Podcasts are video or audio clips that users can listen to or watch from a remote location using a computer,
iPod, or smartphone (among other things). Id.
157 Video sharing allows the public to upload video clips to the internet. YouTube is an example of a video
sharing site. Id.
158 Social networks and online communities allow users to connect with others. These include sites like
Facebook and Linkedln. Id.
159 The FDA defines widgets as "a graphic control on a Web page that allows the user to interact with it in
some way. Widgets can also be posted on multiple Web sites, have the added benefit of hosting 'live' content,
and often take the form of on-screen tools..." which include stock tickers, countdowns, weather updates, etc.
Id.
160 Wikis are web pages that anyone with access can modify. Wikipedia is an example of a wiki that anyone
can modify. Id.
161 Id.
162 Id. at 48086-87. The FDA also solicited comments on internet adverse event reporting, which is not a topic
addressed by this note.
163 See Public Hearing on Promotion of FDA-Regulated Medical Products, supra note 36.
'64 See id. at 1-5.

165 See Notice of Public Hearing, supra note 153, at 48086.
166 Public Hearing on Promotion of FDA-Regulated Medical Products, supra note 36, at 33-34. It is noted that
as of September 2, 2011, Sidewiki has been discontinued by Google in order to "focus instead on [their] broader
social initiatives." A Fall Spring-Clean, OnciAL GOOGLE BLOG, (Sept. 2, 2011, 12:45 PM), http://
googleblog.blogspot.com/2011/09/fall-spring-clean.html.
167 Off-label use refers to a physician's prescribing of a drug for a purpose other than what the FDA has
approved it for. Such use is acceptable "when the intent is the practice of medicine[.]" FoOD & DRUG ADMIN.,
"Off-Label" and Investigative Use of Marketed Drugs, Biologics, and Medical Devices - Information Sheet
(Sept. 10, 2011), http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm.
168 Michele Sharp, Senior Director of U.S. Regulatory Affairs, Eli Lilly & Co., Public Hearing on Promotion of
FDA-Regulated Medical Products Using the Internet and Social Media Tools, FooD & DRUG ADMIN., (Nov. 12,
2009), at 34 (transcript available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedical
ProductsandTobacco/CDERIUCM 93462.pdf).
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Another concern relating to pharmaceutical company liability is misleading information on third party websites. 169 In the initial call for comments, 170 the FDA had requested
commentary about the feasibility of companies policing the entirety of the Internet for false or
17t
misleading information about their products, such as information concerning off-label use,
and correcting it if possible. 172 Specifically, the FDA questioned whether there were any
"criteria that could be used to determine the appropriateness of correcting misinformation and/
or [the] scope of information a company can provide when trying to correct misinformation on
a Web site outside a company's control."' 173 The FDA also asked whether or not the type of
website (blog, reference page, etc.), its prominence (how many people view the website), and
its intended audience should be considered when determining whether corrective action is
necessary. 174 If, for example, a drug company is made aware of misinformation being distributed on a website, comments page, or blog of some kind that they do not control or influence,
the general consensus at the FDA hearing was that companies should not be required to
correct the information. 175 Many presenters agreed, however, that it is in a company's best
interest to keep an eye out for misinformation and attempt to correct it if at all possible. 176 It
77
was also suggested that the corrective information be just that: information, not promotion. 1
Additionally, there was a general consensus at the FDA hearing that whenever an
individual who works for a pharmaceutical company posts corrective or other information, or
contributes to a blog or other forum, full disclosure should be made about the relationship of
the author to the company. 178 Several speakers at the hearing suggested that such transparency falls, could fall, or should fall under the Federal Trade Commission's ("FTC") consumer protection laws requiring prominently placed disclosures when a blogger has been paid
or influenced by an advertiser. ' 79 It was offered that this type of disclosure should be included
169 Notice of Public Hearing, supra note 153, at 48087.
170 id.

171 Id. at 48086. See also text accompanying note 167.
172 Notice of Public Hearing, supra note 153, at 48086.
173 Id.
174

Id.

175 See, e.g., Rohit Bhargava, Senior Vice President, Ogilvy 360 Digital Influence, Public Hearing on
Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools, FooD & DRUG
ADMIN., (Nov. 12, 2009), at 64, (transcript available at http://www.fda.gov/downloads/AboutFDA/Centers
John Mack, Publisher, Pharma
Offices/OfficeofMedicalProductsandTobacco/CDER/UCM193462.pdf);
Marketing News, Public Hearing on Promotion of FDA-Regulated Medical Products Using the Internet and
Social Media Tools, FooD & DRUc ADMN., (Nov. 12, 2009), at 90 (transcript available at http://www.fda.gov/
downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM 193462.pdf);
Maureen Miller, Account Supervisor & Social Media Lead, Compass Healthcare Communications, Public
Hearing on Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools, FooD &
DRUG ADMIN., (Nov. 12, 2009), at 407 (transcript available at http://www.fda.gov/downloads/AboutFDA/
CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM I93462.pdf).
176 Miller, supra note 175, at 407.
177 Id.

178 See, e.g., Wayne Gattinella, President & Chief Executive Officer, WebMD, Public Hearing on Promotion of
FDA-Regulated Medical Products Using the Internet and Social Media Tools, FOOD & DRUG ADMIN., (Nov. 12,
2009), at 162-63 (transcript available at http:l/www.fda.govldownloads/AboutFDA/CentersOffices/Officeof
MedicalProductsandTobacco/CDER/UCM193462.pdf). See also Jeremy A. Greene & Aaron S. Kesselheim,
PharmaceuticalMarketing and the New Social Media, 363 NEW ENG. J. MED. 2087, 2088 (2011).
179 See, e.g., Christopher Schroeder, Chief Executive Officer, HealthCentral, Public Hearing on Promotion of
FDA-Regulated Medical Products Using the Internet and Social Media Tools, FOOD & DRUG ADMIN., (Nov. 13,
2009), at 256 (transcript available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/Officeof
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on any website, blog, or other communication which the company wrote, financed, or had
other influence over, such as sponsorship. 180 It was asserted that transparency promotes trust
with consumers who view the information t8 and helps avoid confusion about the source of
1 82
the information provided in order to aid consumers in their search for accurate information.
Perhaps the biggest challenge and concern for the FDA and pharmaceutical industry
is fulfilling the brief summary requirement on the Internet, specifically in a small amount of
space, such as a Tweet or one or two line sponsored advertisement, without falling afoul of the
current regulations' 83 and what role links play in that equation. 184 Pharmaceutical companies
have generally followed a "one-click" rule in regards to links on the Internet. i" 5 The one-click
rule is an industry-created practice that assumes that it is sufficient to present some information about a drug, absent risk disclosure, so long as information regarding risk is only "one
click away".' 86 This practice was widespread until 2009, when the FDA sent warning letters
to fourteen pharmaceutical manufacturers relating to sponsored links on an Internet search
engine. 187 The letters to Pfizer, for example, described links that were just above the search
results on a page and highlighted in a light peach color with the words "sponsored link" in the
upper right hand corner. 18 8 The FDA found that each sponsored link was misleading because
they made efficacy claims about the drug without providing any risk information at all.' 89 The
one line ads said things such as "learn about AROMASIN, a treatment for women with breast
cancer", "www.LYRICA.com Diabetic Nerve Pain, Add-on for Partial Seizures & Fibromyalgia", and "CADUET.com Treat High Blood Pressure and High Cholesterol with One
Pill."' 190 The FDA told Pfizer that while they recognized that they could access the full drug
information by clicking on the link, it was "insufficient to mitigate the misleading omission of

MedicalProductsandTobacco/CDERIUCM193463.pdf); Arnold Friede, Principal, Arnold I. Friede & Assoc.,
Public Hearing on Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools,
FOOD & DRUG ADMIN., (Nov. 12, 2009), at 103-08 (transcript available at http://www.fda.gov/downloads/
AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDERIUCM193462.pdf).
180 See, e.g., Tiffany Mura, Director of Digital Strategy, Consensus Interactive, Public Hearing on Promotion
of FDA-Regulated Medical Products Using the Internet and Social Media Tools, FOOD & DRUG ADMIN., (Nov.
12, 2009), at 220-24 (transcript available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/Officeof
MedicalProductsandTobacco/CDERIUCM 193462.pdf).
' Jack Barrette, Chief Executive Officer, WEGO Health, Public Hearing on Promotion of FDA-Regulated
Medical Products Using the Internet and Social Media Tools, FooD & DRUG ADMIN., (Nov. 12, 2009), at 183,
(transcript available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsand
Tobacco/CDER/UCM 193462.pdf).
182 Schroeder, supra note 179, at 255. See also Greene & Kesselheim, supra note 178.
193 Greene & Kesselheim, supra note 178, at 2088.
184 Notice of Public Hearing, supra note 153, at 48087.
185 Doug Flora, The FDA and Social Media: A Primer, THE FOSBURY FLOP (Sept. 27, 2010), http://

thefosburyflop.com/2010/09/27/the-fda-and-social-media-a-primer/.
186 id.
187 See Greene & Kesselheim, supra note 178.
188 To view screenshots of the promotional material in question, see Presentation of Amy Cowan, Head of
Indus., Google, Public Hearing on Promotion of FDA-Regulated Medical Products Using the Internet and
Social Media Tools, FOOD & DRUG ADrNU, (Nov. 12, 2009), http://www.fda.gov/downloads/AboutFDA/
CentersOffices/OfficeofMedicalProductsandTobacco/CDERJUCM 195758.pdf.
189 Letter from Shefali Doshi, Division of Drug Marketing, Advertising, and Communications, FooD & DRUG
ADMIN., to Robert B. Clark, Vice-President, U.S. Regulatory, Pfizer, Inc. (March 26, 2009), available at http://
www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformationEnforcementActivitiesbyFDA/
WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM 143487.pdf.
190 Id.
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risk information from these promotional materials."' 19 1 The FDA was especially concerned
192
because one of the medications had a boxed warning, and another a bolded warning.
At the hearing, the one-click rule garnered both support and criticism. One presenter
suggested that it is the most effective way to include important information without hindering
a company's ability to participate in media with space constraints such as Twitter. 193 Another
claimed that because clicking through to other information is the "de facto way a consumer
navigates, [and] accesses information" on the Internet, the one-click rule should be the standard.' 9 4 The representative from WEGO Health provided data from a survey they conducted' 95 which found that nearly seventy-two percent of respondents agreed that
pharmaceutical companies should be required to make the regulatory-mandated information
available "one click away". 196 It was pointed out, however, that the one-click rule actually
violates the FDA regulation requiring a fair balance of information if the one or two line
sponsored ad makes indication and/or efficacy claims paired with the branded name of the
97
drug absent risk information.'
Donna Wray, Executive Director of TGaS Advisors, recognized that the FDA has
indicated that the one-click rule is not enough, and thus recommends that sponsored advertisements should be in the form of reminder or unbranded help-seeking type advertisements, at
least until the FDA issues clear guidance. 1 98 After an assessment of click-through rates on
sponsored advertisements before and after the FDA's 2009 warning letters were issued,
Google believes that the reminder and help-seeking advertisements are not as relevant, transparent or useful to a user's search as traditional sponsored advertisements. 199 They suggested
a new format for sponsored advertisements 2 00 that would include both the brand name and
generic, as well as indication, benefit, and risk information. 2 0 ' The advertisement would in-

191 Id.
192 Id. Boxed

warnings can indicate (among other things) that a drug has the potential for an "adverse reaction

so serious in proportion to the potential benefit from the drug ... that it is essential that it be considered in
assessing the risks and benefits of using the drug." Fooo & DRUG ADMIN., Guidance for Industry on Warning
and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drugs
and Biological Products - Content and Format, 11 (Oct. 2011) available at http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM075096.pdf.
193 Bhargava, supra note 175, at 63-64.
194 Ben Wolen, Chief Executive Officer, Waterfront Media, Inc., Public Hearing on Promotion of FDARegulated Medical Products Using the Internet and Social Media Tools, FDA, (Nov. 12, 2009), at 295
(transcript available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsand
Tobacco/CDER/UCM193462.pdf).
195 The survey respondents were members of WEGO Health's "social network". Jack Barrette, the CEO, states
that they are the "top ten percent of creators and editors who really do create content on average for an audience
Barrette, supra note 181, at 174-75. Author's note: It is unknown
of 10,000 or more people every month.

how many people were surveyed.

187.
197 Mack, supra note 175, at 88.
198 Donna Wray, Executive Director, NGaS Advisors, Public Hearing on Promotion of FDA-Regulated
196 Id. at

Medical Products Using the Internet and Social Media Tools, FOOD & DRUG ADMIN., (Nov. 13, 2009), at 308
(transcript available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsand
Tobacco/CDERIUCM193463.pdf).
199 Cowan, supra note 110, at 438-40.
200 An example of this proposed format can be found in the Google hearing presentation. Presentation of Amy
Cowan, supra note 188.
201 Cowan, supra note l10, at 440-441.
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clude two links, one that lands on the company-sponsored product website and another, directly following the risk information, which links directly to the relevant safety
information.20 2 Google also presented a template for sponsored advertisements for drugs that
have a boxed warning. 20 3 In their model, they have the same two line set-up as with a regular
advertisement, but the risk information states: "Click to see full prescribing and risk information, including boxed warning." 204 The advertisement for a drug with a boxed warning does
not give the indication of efficacy information for the drug, to avoid falling afoul of the brief
20 5
summary requirement.
Although one presenter thought that "one click away is one click away too many"
for risk information, 20 6 another made the argument that having the risk information merely a
click away makes it more likely that people will actually see the important risk information.20 7 When "adequate provision" is made in a television ad, for example, viewers are directed to look for full prescribing and risk information either on the Internet or in a print
advertisement due to the lack of time or space to present all of the necessary information in
that media.20 8 Arnold Friede, a Food and Drug attorney who once worked in the FDA's
Office of the General Counsel, sees the adequate provision requirement as broad enough to
include disclosures on the Internet. 2 9 Wayne Gattinella of WebMD posited that the Internet
is unique in that the information is all right at hand and easily accessible; thus if an individual
were directed to click a link to receive risk information, they would be more likely to do that
than they would be to look up risk information in a print source after seeing a similar adver2 10
tisement on television.
Finally, there was discussion about how to verify that the information consumers are
linking to is fair and unbiased. 2 11 For example, Jeffrey Francer of PhRMA suggested that
there could be a type of official FDA logo or symbol that could be placed next to a standardized link that states "All drugs have risks. Click here for important safety information from the
manufacturer." 2 12 Francer believes that the use of the FDA's own logo and consistent, standardized use of the link would lend credibility to the linked information, allowing consumers
to easily identify FDA-regulated information.2 1 3 When one of the FDA panelists asked for
clarification about the information that would be on the linked website, Francer indicated that
the content on that site should be something that the FDA has actually reviewed and approved,
202
203

id.
See supra text accompanying note 192.

204 See Cowan, supra note 110.
205 See id.

206 Diana Zuckerman, President, Nat'l Research Ctr. for Women and Families, Public Hearing on Promotion of
FDA-Regulated Medical Products Using the Internet and Social Media Tools, FooD & DRUG ADMIN., (Nov. 12,
2009), at 194 (transcript available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/Officeof
MedicalProductsandTobacco/CDERUCM 193462.pdf).
207 Gattinella, supra note 178, at 158-60.
201 Id. at 158-60.
209 Friede, supra note 179, at 104-06.

210 Gattinella, supra note 178, at 158-60.
211 See e.g. Jeffrey Francer, Assistant Gen. Counsel, PhRMA, Public Hearing on Promotion of FDA-Regulated
Medical Products Using the Internet and Social Media Tools, FooD & DRUG ADMIN., (Nov. 12, 2009), at 75-76,
(transcript available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsand
Tobacco/CDER/UCM193462.pdf).
212 id.

213 Id. at 75-77.
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such as the labeling or package insert, not just information meeting the fair balance requirement.2 14 Additionally, Francer does not think that just anybody should be able to use the
symbol and standardized link, but only those who have submitted the linked information to
2 15
the FDA, i.e. manufacturers exclusively.
Two years after the FDA public hearing, the FDA finally released a draft guidance
relating to social media. 2 16 Unfortunately for those awaiting this exciting development, the
guidance did not address DTC advertising at all, but only addressed how pharmaceutical companies should respond to unsolicited requests for off-label information about their products. 2 17 In the public context of a company controlled or third-party website or blog, for
example, the FDA recommends responding to a question about off-label use of the company's
drug with a statement that the question concerns an unapproved use and with contact information for further inquiries. 2 18 As yet, there has not been any indication from the FDA as to
when guidance will be issued regarding DTC advertising specifically, although an FDA
2 19
spokesperson suggested that this guidance was only one of many to come.
B.

How DTC Advertising on the Internet Has Been Addressed in the EU

Other than the outright ban on DTC advertising and the proposed Directive that
allows for the dissemination of objective pharmaceutical product information directly to consumers, 220 the EU has not directly addressed the problem of the Internet in the same manner
as the U.S. It appears that the EU's main focus is ensuring that consumers are only able to
"pull" information from Internet sources 22 1 such as U.S. pharmaceutical company websites. 222 It is suggested that the EU "tend[s] to turn a blind eye to the fact that DTC advertising is currently a reality for patients globally...-223 i.e., that the information is, in fact, being
"pushed" at Internet users in the form of DTC advertising currently.
There have been two recent decisions handed down by the Court of Justice of the
European Union concerning DTC advertising on the Internet that shed some light on the EU's
position. 224 The first was a criminal proceeding against Frede Damgaard, a journalist who had
a history of writing about natural products on the Internet.2 25 The proceedings against Damgaard were brought by the public prosecutor of Denmark, who claimed that Damgaard had
83-84.
Id. at 84-85.

214 Id. at
215

216See GUIDANCE FOR INDUSTRY: RESPONDING TO UNSOLICITED REQUESTS FOR OFF-LABEL INFORMATION
ABOUT PRESCRIPTION DRUGS AND MEDICAL DEVICES, FOOD & DRUG ADMIN. (2011).

217 Rich Thomaselli, FDA's Social Media 'Guidelines' Befuddle Big Pharma, AD AGE DIGITAL (Dec. 30,
2011), http://adage.com/article/digital/fda-s-social-media-guidelines-befuddle-big-pharma/231855/.
218 GUIDANCE FOR INDUSTRY, supra note 216, at 11.
219 Thomaselli, supra note 217.
220 See supra Part Il.B.
221 Barratt, supra note 53, at 51.
222 Id.
223 Id.

224 Case C-421/07, Criminal Proceedings Against Frede Damgaard, 2009 E.C.R. 1-02629; Case C-316/09,
MSD Sharp & Dohme GmbH v. Merckle GmbH, May 5, 2011 (not yet published), available at http://
cruia.europa.eu.
225 The ANH Team, European Court Ruling Infringes Freedom of Speech, ALLIANCE FOR NATURAL HEALTH
(Apr. 3, 2009), http://www.anh-europe.org/news/european-court-ruling-infringes-freedom-of-speech.
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violated the Community Directive 2 26 relating to medicinal products for human use. 227 Damgaard had written an article about a natural remedy, and reported that the treatment contained
rosehip powder, for which he stated the product's usage indications. 22 8 Although Damgaard
had absolutely no connection to the company that produced the product, nor any other similar
company, 229 the Court found that "the wording of Directive 2001/83 does not rule out the
possibility that a message originating from an independent third party may constitute advertising. Nor does the directive require a message be disseminated in the context of commercial or
industrial activity in order for it to be held to be advertising." 230 Thus, it may possible for
anyone who disseminates information about the indications for use of a medicinal product (in
this case not even a product requiring a prescription) to be held criminally liable for violation
23 1
of the EU policy on medicinal products advertising.
The second case of interest relates to information obtained via a pharmaceutical
company's website. 232 There were two questions presented in the case: whether or not Directive 2001/83 extends to "advertising [that] contains only information which was placed before
the authorising authority in the course of the marketing authorisation procedure and which is
accessible ... to every person acquiring the product...233 and whether the Directive extends
to cases where the information is not unsolicited, but "can be accessed only through the Internet when the party concerned takes steps to do So[.]"234 The information in question was a
direct recitation of the packaging, the instructions in the package leaflet, and the therapeutic
23 5
indications for the medications in question.
On the first question, the Court held that when the information distributed is a direct
recitation of the already-approved packaging and leaflet information, it is acceptable that it be
provided on the company's website. 236 Interestingly, the Court also declared that such objective information, when obtained prior to a medical appointment, could contribute to the prescribing of an appropriate medication, "in so far as there may be a more fruitful dialogue
between the doctor and the informed patient" 23 7 and that it could help avoid "uninformed
self-medication" by patients who no longer had access to the package leaflet for the medica238
tion they had been prescribed.
On the second question, the Court made a distinction between the "push" and "pull"
of information from the Internet. 239 In noting that the information on the website could only
be accessed by "pulling" it, the Court posited that "itihat means of communicating information with the assistance of a passive presentation platform is not, in principle, intrusive and
226
227
228
229
230
231

See generally Council Directive 2001/83/EC, supra note 111.
Case C-421/07, Criminal Proceedings Against Frede Damgaard, 2009 E.C.R. 1-02629.
Id.at 10-11.
Id.at 1 12.
Id.at 21.
It is noted that Denmark, which brought the proceedings against Mr. Damgaard, does not allow

advertisement even of non-prescription medications. Id.at 1 12. This, however, does not affect the Court of
Justice's reasoning that such activity could be deemed "advertising".
232 See Case C-316/09, supra note 224.
233 Id.at 1 19.
234 Id.

235 Id.at
236 Id.at
237 Id.at
238 Id.at

40.
43.
38.
39.

239 Id. at 1 47.
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does not impose itself unexpectedly on the general public." 24 It is thus distinguishable from
"push" services, "in which an Internet user is confronted, without searching for it, with that
kind of content by means of intrusive windows called 'pop-ups',... from which situation a
strong presumption of advertising must, by contrast, be inferred. '24 1 Essentially, this holding
had firmly planted at least part of the Commission's rejected 2008 proposed Directive into EU
law 242 even before the new proposal was approved.
It appears that by only addressing the type of information that can or cannot be
"pushed" on consumers, the EU is missing the point. Internet users who seek out health information are still going to have advertising "pushed" at them in the form of sponsored links if
their search leads them to information from the U.S., thus the distinction is nearly meaningless. If the EU's purpose is truly to "better protect [the] health of EU citizens," 243 it must
address, and perhaps even legalize and regulate, the use of DTC advertising on the Internet by
pharmaceutical companies in the EU. The question then turns to how U.S. and EU regulatory
agencies can go about undertaking the monumental task of creating a standardized regulatory
framework which promotes accurate information, and in which pharmaceutical companies can
participate in the consumer market by advertising their products without fear of liability.
IV.

WHERE DO WE GO FROM HERE?

It would be impossible to completely harmonize and integrate the use of DTC advertising between the U.S. and the EU, if only due to the fact that different drugs are approved in
different countries, and often for different purposes. 244 That does not, however, mean that
those regions that have a high incidence of Internet health information seeking by the lay
public cannot attempt to standardize DTC advertising so that it is clear to the consumer from
the outset what type of information they are looking at. As the sheer quantity of presentations
at the FDA hearing show, 24 5 pharmaceutical advertising on the Internet is an important issue
involving many stakeholders, and not just in the United States. While the European Union
faces similar challenges regarding DTC advertising over the Internet, they do not take as
proactive a stance as the FDA does. The use of the Internet as an advertising mechanism has
huge potential to educate the public about health and medical treatment. The FDA and European Parliament should take this opportunity to enhance the quality and insure the standardization of information being distributed to the public through that medium. That is not to say
that DTC advertising on the Internet should be eliminated and replaced solely with educa240 Id.
241 Id.

242 Although the language is not the same, the effect of the ruling is directly in line with the proposal, which
stated that information "be made available through... internet websites on medicinal products, to the exclusion
of unsolicited material actively distributed to the general public or members thereof." Proposal for a Directive,
COM (2008) 663, supra note 127, at 14.
243 Amended ProposalCOM (2011) 663, supra note 136, at 2.
24 See generally Lisa Richwine, Study: Cancer Drugs Approved in U.S. Before Europe, REUTERS (June 16,
2011), http://www.reuters.com/article/2011/06/16/us-cancer-drugs-approval-idUSTRE75FICD20110616
(indicating that different countries approve different drugs).
245There were fifty presentations relating to the issues discussed supra at the two-day hearing, not including
the presentations dealing only with the Adverse Event Reporting issue. See Presentationsfrom Public Hearing
on Promotionof FDA-Regulated Medical Products Using the Internet and Social Media Tools, FooD & DRUG
ADMIN., http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm
192703.htm (last updated Feb. 25, 2010).
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tional content, as that would probably create a severe conflict of interest. 24 6 DTC advertising
is most likely here to stay and probably does provide at least some benefit to the public health
247
by encouraging consumers to seek more information and talk to their doctor.
The nature of the Internet and pharmaceutical advertising in that medium ameliorates some of the negative impacts of DTC advertising put forth by critics. 248 Because the
majority of pharmaceutical promotion on the Internet is in the form of one or two line, text
only advertisements, 24 9 it is possible to promote prescription drugs without the fear of making
emotional or manipulative appeals to consumers and patients. 250 That type of sponsored advertisement does not leave room for emotional appeals or manipulation, at least during the
patient's first contact with it. 25 1 From there, the first information a consumer sees should be a
fair and balanced portrayal of the risks and benefits of the drug prominently placed on the
screen, much like what is currently required by the regulations for print advertisements. 252 It
is imperative that the information presented uses clear language that allows a person of aver253
age intelligence to understand it fully.
Potentially, the nearly unlimited amount of space available on the Internet gives
pharmaceutical companies less incentive to make advertisements biased or unbalanced. Rather
than pharmaceutical companies picking and choosing which information they want to convey,
they can convey all such information through a system of web pages connected with links.
While it is true that the purpose of pharmaceutical advertising is to make a profit,254 that
primary goal does not necessarily preclude the possibility that advertising can be of some
educational value.25 5 If companies are not constrained to two pages in a magazine or a thirty
or sixty second television spot, it is less likely that they will try to fit all of the "good"
information in, while leaving out the "bad," thus relieving some of the concern over biased
256
information.
The allowance of the use of the one-click rule is imperative to pharmaceutical companies' ability to sponsor advertisements on search pages and to participate in some forms of
social media, such as Twitter or Facebook. 257 Although the FDA has indicated that reliance

246
247

See
Id.

WEBER,

supra note 3, at 161-64.

248See supra Part I.

249 See supra Part lI.A.
250 See supra Part H.A.
251See Presentation of Amy Cowan, supra note 188, at 12-13.
252 See 21 C.F.R. § 202.1(e)(1) (2011).
253 See, e.g., Bill Drummy, CEO, Heartbeat Digital, Public Hearing on Promotion of FDA-Regulated Medical
Products Using the Internet and Social Media Tools, FOOD & DRUG ADMIN., (Nov. 13, 2009), at 273-86
(transcript available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsand
Tobacco/CDER/UCM 193463.pdf).
254 See WEBER, supra note 3, at 162.

255 See id. at 162-63. Weber believes that there is an inherent tension between the goal of advertising (profits)
and the goal of educating the public. "Given [pharmaceutical companies'] commercial goals, it is not reasonable
to expect that they have the kind of objectivity that is essential for true education." See id. at 163. He does think
that consumers can gain knowledge from advertisements and that combining that knowledge with other
information they receive can lead to improved healthcare. Id; but see MARCIA ANGELL, THE TRUrH ABOUT THE
DRUG COMPANiES 250-53 (2004).

256 See supra Part I.
257 See supra Part III.
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on the one-click rule is not acceptable, 25 8 it probably complies better with the adequate provision requirement than traditional television or radio broadcasting, if only because the informa259
tion is immediately accessible with one easy click. As was mentioned at the FDA hearing,
links are the quintessential way that Internet users navigate for information, 2 60 thus having
risk information merely one click away from the sponsored advertisement or Twitter post
would seem to be a logical progression for Internet users. This rule should be paired with a
fairly-balanced sponsored advertisement, such as the one proposed by Google which would
list the pertinent information and provide two links, one to the company website and the other
to safety information. 26 1 The use of the term "box warning" in an advertisement is probably
ill-advised, as it is unlikely that most consumers would understand that such language indicates heightened risk information.
Consistent with clear language and fairly-balanced information, several speakers at
the FDA hearing mentioned the possibility of some type of "seal of approval" that could be
placed on websites bearing pharmaceutical information. 262 This idea has potential in that it
would help consumers immediately determine whether or not the FDA, or perhaps an international third-party organization that would specialize in such certification, has approved of the
information. Stringent guidelines for seal approval would have to be in place, and they should
not be fulfilled easily. However, if a device or seal were standard across the Internet, consum263
ers would at least have some guidance as to the quality of information they were receiving.
Of course, consumers would still be free to seek out uncertified information, but having a seal
of approval would make quality health information more readily apparent to the consumer,
which would probably benefit many users, especially those without much knowledge of the
Internet.
Finally, as the majority of speakers at the FDA hearing agreed, pharmaceutical companies should only be responsible for the information they create and control. 264 Companies
should have the option to attempt to correct inaccurate information about their products on the
Internet whether it is posted on their website or on a third-party website, and it is in their best
interest to do so in order to help protect the public health. 265 It would be asking too much of
any company, not just those that manufacture pharmaceuticals, to police the entirety of the
Internet for every inaccurate mention of their product. Liability for misinformation, though,
should include any information over which the company has control or influence, and such
connections should be displayed prominently to further clarify to consumers the source of the
266
information.

258 See supra Part HI.A. See also supra text accompanying note 110.
259 See supra Part HI.A.
260 See Id.
261 See supra part Ill.
262 See Id.
263 See Rafael Bauschke, Regulatory Agencies, PharmaceuticalInformation and the Internet: A European
Perspective, 104 HEALTH POL'Y 12, 13 (2012).
264 See supra part Ill.
265 See Id.
266 See Id.
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CONCLUSION

The FDA has considerable work ahead of it. Implementing changes of the magnitude
necessary to fully standardize the way DTC advertising is practiced on the Internet will take
time and ingenuity, primarily because the way that users interact with the Internet is constantly changing. Of some consolation is the fact that the FDA already has many of the necessary regulations in place, 267 and many may only require clarification or extensions relating to
their application to DTC advertising on the Internet specifically. Confusion over how to fulfill
the brief summary requirement, for example, could easily be mitigated by standardization of
sponsored links and the endorsement of the one-click rule. Ultimately the FDA must provide
clarification for the pharmaceutical industry. The FDA must issue guidance indicating what
forms of advertising on the Internet are acceptable.
The EU should rethink its stance on the practice of DTC advertising, especially on
the Internet. By completely rejecting the idea of DTC advertising, they are rejecting an opportunity to influence the information that consumers receive despite the EUs objections. By
allowing some forms of strictly regulated DTC advertising, even if it only applies to the
Internet, the EU will be in a position to have at least some control over the type of information
consumers see. It is better to have strictly regulated but helpful information advertised to
consumers, than it is to have consumers seek out information that may or may not be accurate
or useful. By ignoring the fact that consumers in the EU seek information about pharmaceuticals on the Internet and are often exposed to DTC advertising, the EU is doing a disservice to
their citizens.

267 See supra part II.A.
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